论文部分内容阅读
目的通过对不同类型乳腺组织和乳腺癌中SGK3的表达情况进行分析,初步探讨SGK3与乳腺癌临床病理特征的相关性。方法利用免疫组化方法,检测SGK3在正常乳腺组织和乳腺癌组织中的表达,进一步研究SGK3在不同类型乳腺癌以及同一类型不同病理分级乳腺癌组织中的表达情况,并结合临床参数探讨SGK3与乳腺癌临床病理特征的关系。结果 (1)免疫组化结果显示,乳腺癌组织中蛋白激酶SGK3表达量增高,与正常乳腺组织和癌旁组织相比,有差异(P值分别为0.007,0.016)。(2)SGK3在乳腺纤维腺瘤、叶状囊肉瘤以及导管内癌的表达量极低,与正常乳腺组织相比差异无统计学意义(P值分别为0.076,0.365,0.500);而在浸润性导管癌中的表达明显增高(P值为0.041)。(3)SGK3的表达不受浸润性导管癌的分期影响,但与ER受体表达密切相关,雌激素受体(ER)阳性的浸润性导管癌与ER阴性的浸润性导管癌相比组织中SGK3的表达量明显增高(P值为0.033)。结论 SGK3在乳腺浸润性导管癌组织中呈高表达,且在ER阳性的润性导管癌组织中的表达高于ER阴性组织,SGK3有可能成为乳腺浸润性导管癌临床诊断和预后的指标。
Objective To investigate the relationship between SGK3 and clinicopathological characteristics of breast cancer by analyzing the expression of SGK3 in different types of breast tissues and breast cancer. Methods The expression of SGK3 in normal breast tissues and breast cancer tissues was detected by immunohistochemistry. The expression of SGK3 in different types of breast cancer and in different pathological grades of breast cancer tissues was further studied. The clinical parameters SGK3 and Relationship between clinical and pathological features of breast cancer. Results (1) The results of immunohistochemistry showed that the expression of protein kinase SGK3 increased in breast cancer tissues compared with normal breast tissues and adjacent tissues (P = 0.007, 0.016, respectively). (2) The expression of SGK3 in breast fibroadenoma, cystocytic sarcoma and intraductal carcinoma was extremely low, with no significant difference compared with normal breast tissue (P = 0.076,0.365,0.500, respectively) The expression of VEGF in ductal carcinoma was significantly higher (P = 0.041). (3) The expression of SGK3 was not affected by the staging of invasive ductal carcinoma, but closely related to the expression of ER receptor. Compared with ER-negative invasive ductal carcinoma, estrogen receptor (ER) -positive invasive ductal carcinoma SGK3 expression was significantly increased (P value of 0.033). Conclusion The expression of SGK3 is highly expressed in invasive ductal carcinoma of the breast. The expression of SGK3 in ER-positive ductal carcinoma is higher than that in ER-negative tissues. SGK3 may be an indicator of clinical diagnosis and prognosis of invasive ductal breast cancer.